Washington
Q3 2026Lobbying Q3 None last Q1 2025
YoY n/a vs Q3 2025
Members 0 90 days
Buys / sells 0 / 0 0 trades
8 quarters Open in Washington ›
BLGO
BIOLARGO, INC.$0.0700 +0.00 (+0.00%)
Oct 26 4:00 PM ET · prev $0.0700
Median target
$0.3000
+329% · range $0.3000–0.3000
Next earnings
Nov 11
in 15 days · EPS est. −$0.01
1 year
−58.8%
from $0.1700 · Oct 27
30 days
−22.2%
from $0.0900
52-week range
$0.0700–0.2000
−65% from high · low Oct 6
Avg volume 20D
391.5K
Oct 5 spike 1.43M
Short interest
🔒 Subscribers only
Insider net
$0
no open-market trades · 12 mo
Filing reports
6
analyzed by SecBot
SecBot read BEARISH 2 reports · 90 days
Balance 1 bearish · 0 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 1/2 ·Next Earnings date, Nov 11, 2026
Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
No data for this timeframe.
- R Mar 5 BioLargo reported its 2025 annual results, showing a significant rev…
- R Apr 17 This 424B4 filing relates to the offering of 31,730,651 shares of Bi…
- R Apr 17 BioLargo is registering 30 million shares for resale by Clearthink C…
- X Jul 31 Short interest falls 75.7% to 24.7K
- X Aug 31 Short interest falls 61.9% to 8.9K
- X Sep 15 Short interest falls 88.6% to 1.0K
- X Sep 30 Short interest falls 98.0% to 20
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
- EstimatesFLAT
Current-quarter EPS estimate −$0.010 → −$0.010 over 90 days.
- TrendDOWNTREND
20% below its 50-day average. New closing low $0.0700 on Oct 26.
- SocialQUIET
No Reddit mentions this week. Last mention Oct 2.
The Street
12-month targets · 1 analysts
$0.0700 $0.3000 $0.3000 $0.3000
Price is below the lowest target. Median implies +329%.Targets as of Oct 27, 2026.
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Recent
Reddit
Recent posts
$BLGO ViaCLYR is commercial now, BioClynse is next, and Clyra’s $100M value was paid for - not imagined
1 upvotes · 6 comments
$BLGO - Keep an eye on it
1 upvotes · 1 comments
Insider ledger
Form 4$0
open-market buys or sells · 12 mo
| Date | Insider | Type | Value |
|---|---|---|---|
| Sep 30, 2026 | Park Linda Director | AWARD | 234,375 sh |
| Sep 30, 2026 | Bray Christina Elaine Director | AWARD | 234,375 sh |
| Sep 30, 2026 | STROMMEN JACK B. Director | AWARD | 187,500 sh |
| Sep 30, 2026 | Marshall Dennis E Director | AWARD | 281,248 sh |
| Sep 30, 2026 | Marshall Dennis E Director | AWARD | 234,375 sh |
| Sep 30, 2026 | CALVERT DENNIS P President | AWARD | $74.6K |
| Sep 30, 2026 | CALVERT DENNIS P President | GIFT | 2,000,000 sh |
| Sep 30, 2026 | CODE KENNETH REAY Chief Science Officer | AWARD | $45.3K |
Earnings setup
EstimatesNov 11
reports in 15 days
−$0.01
EPS estimate, this quarter
0%
estimate change, 90 days
Current-quarter EPS estimate
−$0.01090d
−$0.01060d
−$0.01030d
−$0.0107d
−$0.010Now
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.01 | -$0.01–-$0.01 | +0.0% | $1.4M |
| Next Q | -$0.01 | -$0.01–-$0.01 | +0.0% | $1.5M |
| Current FY | -$0.05 | -$0.05–-$0.05 | -25.0% | $5.2M |
| Next FY | -$0.03 | -$0.03–-$0.03 | — | $15.8M |
Short side
FINRA· Oct 15, 2026🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 19, 2026 SEC
BioLargo's 2026 definitive proxy statement schedules director elections, an advisory say-on-pay vote, and ratification…
DEF 14A — Impact 5/10
Sep 30, 2026 Insider
Park Linda was granted 234,375 shares
Director
Sep 30, 2026 Insider
Bray Christina Elaine was granted 234,375 shares
Director
Sep 30, 2026 Insider
Sep 11, 2026 SEC STROMMEN JACK B. was granted 187,500 shares
Director
BioLargo, Inc. filed a Form 8-K on September 10, 2026, to disclose a slide deck presentation (Exhibit 99.1) that was…
8-K — Impact 2/10
Aug 12, 2026 Earnings calendar
May 4, 2026 SEC BLGO Q2 2026 Earnings Scheduled — 2026-08-12
BioLargo announced that CEO Dennis P. Calvert will participate in a town hall meeting hosted on the BioLargo…
8-K — Impact 1/10
SecBot reports
6 filings · 0 bullish · 4 bearish · 2 neutral- BEARISH DEF 14AOct 19, 2026
BioLargo's 2026 definitive proxy statement schedules director elections, an advisory say-on-pay…
The 56% revenue collapse and tripling of net losses signal severe operational deterioration. Monitor the next 10-Q for evidence of a turnaround or further cash burn; the proxy's lack of shareholder…
- NEUTRAL 8-KSep 11, 2026
BioLargo, Inc. filed a Form 8-K on September 10, 2026, to disclose a slide deck presentation…
This is a routine investor presentation filing with no new financial data or guidance. Monitor for future 10-Q or 8-K filings for operational or financial updates. No immediate trading action…
- NEUTRAL 8-KMay 4, 2026
BioLargo announced that CEO Dennis P. Calvert will participate in a town hall meeting hosted on…
Monitor the upcoming 8-K filing of the town hall transcript for any material business updates. The event itself is not a catalyst, but the transcript may contain forward-looking commentary worth…
- BEARISH 424B4Apr 17, 2026
This 424B4 filing relates to the offering of 31,730,651 shares of BioLargo common stock by selling…
The significant dilution from warrant exercises combined with declining revenue and ongoing litigation creates substantial downside risk. The company's ability to continue as a going concern is in…
All BLGO filing & press-release reports (6)
- DEF 14A reportOct 19, 2026
- 8-K reportSep 11, 2026
- 8-K reportMay 4, 2026
- 424B4 reportApr 17, 2026
- 424B4 reportApr 17, 2026
- 8-K reportMar 5, 2026